| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008904 For therapy of angina pectoris, atherosclerosis, hypertension and hyperlipidemia |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008896 Isoquinolinone derivatives |
| 01/09/2003 | US20030008894 Antimicrobial quinolones, their compositions and uses |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008890 For therapy of neurological and psychological disorders |
| 01/09/2003 | US20030008883 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008880 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
| 01/09/2003 | US20030008879 For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008874 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists |
| 01/09/2003 | US20030008871 Administering sulfonyl pyridazinone compounds for therapy and prophylaxis of tissue damage resulting from ischemia |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008867 Compounds |
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008863 Novel tricyclic diazepines tocolytic oxytocin receptor antagonists |
| 01/09/2003 | US20030008862 Function as sulfatase and/or blocking estrogen receptors; prophylaxis and therapy |
| 01/09/2003 | US20030008854 Use of NF-kappabeta inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008852 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 01/09/2003 | US20030008846 Use of dopamine receptor antagonists in palliative tumor therapy |
| 01/09/2003 | US20030008844 Administering formulatin comprising iduronylglycosaminoglycan sulfate and dermatan sulfate or their salts, solvates, hydrates or clathartes for therapy and prophylaxis of inflammatory bowel disease |
| 01/09/2003 | US20030008843 Bulking agents as satiety agents |
| 01/09/2003 | US20030008842 Formulations of adenosine a1 agonists |
| 01/09/2003 | US20030008841 Anti-HCV nucleoside derivatives |
| 01/09/2003 | US20030008827 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008820 Methods and products related to FGF dimerization |
| 01/09/2003 | US20030008806 Inhibitors of phosphodiesterases (PDEs) such as papaverine for treatment of drug dependence and psychological disorders |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008273 Methods for increasing the survival of neuronal cells |
| 01/09/2003 | US20030008023 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008018 Acrochordon alleviation |
| 01/09/2003 | US20030008016 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 01/09/2003 | US20030007983 Two-hybrid assay that detects HIV-1 reverse transcriptase dimerization |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007963 Treatment of pompe's disease |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007954 Cardiovascular disorder; strokes; gene therapy |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030007932 Drug delivery; overcoated solid dried active solid |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | US20030005889 Method of improving hatchability of eggs |
| 01/09/2003 | CA2455654A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | CA2452390A1 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | CA2452371A1 Use of tyrosine kinase inhibitors for treating allergic diseases |
| 01/09/2003 | CA2452364A1 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452196A1 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | CA2452171A1 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2452105A1 Dibenzocycloheptene compound |
| 01/09/2003 | CA2452092A1 Carbohydrate derivatives |
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/09/2003 | CA2451959A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | CA2451850A1 Medicinal compositions |
| 01/09/2003 | CA2451795A1 Cell-based high-throughput screening methods |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451228A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | CA2451163A1 Agent for preventing or treating organ functional disorders and order dysfunction |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451039A1 Methods for preparation and use of 1.alpha.,24(s)-dihydroxyvitamin d2 |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2447280A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | CA2446580A1 Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications |
| 01/09/2003 | CA2424645A1 New use of dipeptidyl peptidase iv inhibitors |
| 01/09/2003 | CA2419888A1 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 01/09/2003 | CA2418543A1 New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/08/2003 | EP1273657A1 Novel protein, process for producing the same and use thereof |
| 01/08/2003 | EP1273592A2 Process for the purification of pharmacologically active proteins through cationic exchange chromatography |
| 01/08/2003 | EP1273582A1 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272853A2 Methods for identifying and using amyloid-inhibitory compounds |
| 01/08/2003 | EP1272642A2 Coffee mannanase |
| 01/08/2003 | EP1272641A2 Serine-threonine kinase |
| 01/08/2003 | EP1272636A2 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 01/08/2003 | EP1272615A2 Osteocalcin promoter directed adenovirus replicaton for therapy |
| 01/08/2003 | EP1272526A1 Enhancement of antibody-mediated immune responses |
| 01/08/2003 | EP1272516A2 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 01/08/2003 | EP1272515A2 Immunoregulator |
| 01/08/2003 | EP1272509A2 Prion-binding peptidic ligands and methods of using same |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272505A1 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives |
| 01/08/2003 | EP1272504A1 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/08/2003 | EP1272502A2 Dna molecules and polypeptides of pseudomonas syringae hrp pathogenicity island and their uses |
| 01/08/2003 | EP1272490A2 Sodium salt of an azo derivative of 5-aminosalicylic acid |
| 01/08/2003 | EP1272489A1 Process for preparing crystalline form i of cabergoline |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272487A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |